Targeted Radiopharmaceuticals Manufacturing and Supply Chain Summit

The biggest challenges facing targeted radiopharmaceuticals are the highly complex processes associated with acquiring raw radioisotope APIs, the limited availability of these radionuclides, and getting whole-drug products to patients on time. This can't be done alone! Abdera, Clarity, and Rayze have all recently landed landmark supply deals to fuel their clinical development and there are certainly more to come!

The Targeted Radiopharmaceuticals Manufacturing and Supply Chain Summit is the only industry-led meeting dedicated to plugging the gaps in radioisotope supply by developing new sources, designing manufacturing facilities that are scalable, and ensuring safety and quality through well-tested release criteria for whole drug products.

Join us as we unite 80+ key stakeholders in CMC, quality assurance, operations, facility managers, and radiopharmacists to bring the targeted radiotherapies to the forefront of cancer treatment.

Capitalizing on the recent successes this space had over the last year, there has never been this amount of demand and excitement for the TRP community. Take advantage of this platform to hear in-depth challenges and solutions in the global TRP manufacturing landscape.

URLs:
Brochure: https://go.evvnt.com/1729138-1?pid=185
Tickets: https://go.evvnt.com/1729138-2?pid=185
Tickets: https://go.evvnt.com/1729138-3?pid=185

Prices:
Drug Developer Pricing Conference + 2 Workshops: USD 4297.00,
Drug Developer Pricing Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing Conference Only: USD 2999.00,
Solution Providers- Conference + 2 Workshops: USD 5297.00,
Solution Providers- Conference + 1 Workshop: USD 4548.00,
Solution Providers- Conference Only: USD 3799.00

Speakers: Anna Kulesza Director - Chemistry, Manufacturing and Controls  Clovis Oncology, Dan Saragnese Head of Manufacturing  Earli Inc., Diane Abou, Assistant Professor at Washington University in ST. Louis and Lead Chemist at Curium  Washington University School of Medicine, Eric Burak Chief Technical Officer  Fusion Pharmaceuticals, Geoffrey Johnson Chair of Nuclear Medicine  Mayo Clinic, Giuseppe Carlucci Director UCLA Biomedical Cyclotron  University of California Los Angeles, Izabela Tworowska Chief Technology Officer  Radiomedix Inc, Jarrod Longcor Chief Operating Officer  Cellectar Biosciences Inc., Kemp Dolliver Director of Research and Senior Analyst  Brookline Capital Markets, Kevin Roland Vice-President Radiopharmaceuticals manufacturing  Fusion Pharmaceuticals, Michael Nickels Director - Cyclotron Facility  Washington University School of Medicine, Roland Turck Managing Partner  TurckBio, Shaemus Gleason Executive Vice President  Clarity Pharmaceuticals, Shankar Vallabhajosula Scientific Advisor  Convergent Therapeutics, Thomas Birger Eden-Jensen Head of Product Supply Operations  Bayer, Vishnu Dwadasi Director - Manufacturing  Ashvattha Therapeutics, Ying Cai Director - Supply Chain  Ashvattha Therapeutics

Time: 9:00 am to 5:00 pm